According to Fortune Business Insights, the global AI in real-world evidence market size was valued at USD 2.09 billion in 2025. The AI in real-world evidence market is projected to grow from USD 2.70 billion in 2026 to USD 21.00 billion by 2034, exhibiting a CAGR of 29.22% during the forecast period. North America dominated the AI in real-world evidence market with a 48.80% market share in 2025.

The AI in real-world evidence market is witnessing rapid expansion as healthcare organizations increasingly leverage artificial intelligence to generate actionable insights from real-world data collected through electronic health records, insurance claims, patient registries, wearable devices, and other healthcare sources. The growing emphasis on value-based healthcare, personalized medicine, and evidence-driven clinical decision-making is accelerating the adoption of AI-powered analytics across the pharmaceutical and biotechnology industries. AI technologies enable healthcare stakeholders to identify treatment patterns, evaluate patient outcomes, optimize clinical research, and support regulatory submissions with greater speed and accuracy. Pharmaceutical companies are increasingly integrating artificial intelligence into real-world evidence platforms to enhance drug development, post-market surveillance, and market access strategies. Continuous advancements in machine learning, natural language processing, predictive analytics, and cloud computing are improving the efficiency of data processing while supporting better healthcare outcomes. As healthcare systems continue to digitize and generate larger volumes of patient data, the AI in real-world evidence market is expected to experience substantial growth throughout the forecast period.

Continue reading for more details:

https://www.fortunebusinessinsights.com/ai-in-real-world-evidence-market-118102

Market Segmentation

The AI in real-world evidence market is segmented based on component, deployment mode, application, end user, and geography. By component, the market includes software, platforms, and services designed to collect, process, analyze, and interpret real-world healthcare data. Software solutions account for a significant share of the AI in real-world evidence market as healthcare organizations increasingly adopt AI-powered analytics platforms to improve evidence generation and clinical insights. Based on deployment mode, the market includes cloud-based and on-premise solutions, with cloud deployment gaining strong momentum due to its scalability, flexibility, and ability to process large healthcare datasets efficiently. By application, the AI in real-world evidence market covers drug development, pharmacovigilance, regulatory decision-making, clinical research, market access, reimbursement analysis, patient outcome monitoring, and precision medicine. Drug development and clinical research remain leading application areas as pharmaceutical companies seek to accelerate research timelines and improve clinical trial efficiency using real-world data. By end user, the market serves pharmaceutical companies, biotechnology companies, contract research organizations, healthcare providers, regulatory agencies, research institutions, and healthcare payers. Growing investments in artificial intelligence technologies and digital health infrastructure are expected to strengthen every segment of the AI in real-world evidence market over the coming years.

Key Players

• IQVIA Inc.
• Oracle Corporation
• SAS Institute Inc.
• Tempus AI, Inc.
• ConcertAI
• Flatiron Health
• Aetion, Inc.
• Komodo Health, Inc.
• Microsoft Corporation
• IBM Corporation

Market Growth

The AI in real-world evidence market is experiencing exceptional growth due to increasing adoption of artificial intelligence across the healthcare ecosystem and rising demand for data-driven clinical insights. Pharmaceutical and biotechnology companies are utilizing AI-powered real-world evidence platforms to improve clinical development, optimize patient recruitment, monitor treatment effectiveness, and accelerate regulatory approvals. The increasing availability of electronic health records, wearable health technologies, genomic databases, and healthcare claims data is providing vast amounts of information that can be analyzed using advanced AI algorithms. Machine learning and natural language processing technologies enable organizations to identify hidden clinical patterns, predict patient outcomes, and improve disease management strategies with greater efficiency. The AI in real-world evidence market is also benefiting from growing investments in digital transformation initiatives across hospitals, research institutions, and healthcare providers. Strategic collaborations between technology companies, pharmaceutical manufacturers, and healthcare organizations are accelerating innovation and expanding AI capabilities for evidence generation. Governments and regulatory agencies are increasingly recognizing the value of real-world evidence in supporting healthcare decision-making, encouraging broader adoption of AI-based analytical tools. Continuous advancements in cloud computing, big data analytics, and automation are further enhancing the scalability and accuracy of AI solutions. These developments are expected to drive sustained expansion of the AI in real-world evidence market through 2034.

Restraining Factors

Despite its strong growth outlook, the AI in real-world evidence market faces several challenges that could affect its expansion. Data privacy concerns remain a major issue, as healthcare organizations must comply with strict regulations governing the collection, storage, and processing of sensitive patient information. Variations in healthcare data quality, incomplete patient records, and inconsistent data formats may reduce the accuracy of AI-generated insights. Integrating data from multiple healthcare systems, electronic medical records, and insurance databases continues to present technical and operational challenges. High implementation costs associated with advanced AI platforms, cloud infrastructure, and skilled personnel can limit adoption among smaller healthcare organizations. In addition, regulatory uncertainty regarding the use of artificial intelligence in clinical research and evidence generation may slow technology deployment in certain regions. The shortage of AI specialists and healthcare data scientists also creates workforce challenges for organizations implementing advanced analytical platforms. Cybersecurity risks, algorithm transparency concerns, and the need for continuous validation of AI models further increase operational complexity. Addressing these issues through stronger data governance, standardized healthcare data frameworks, enhanced cybersecurity measures, and ongoing regulatory collaboration will remain essential for the long-term success of the AI in real-world evidence market.

Regional Analysis

North America dominated the AI in real-world evidence market with a 48.80% market share in 2025 and is expected to maintain its leadership during the forecast period. The region benefits from advanced healthcare infrastructure, widespread adoption of electronic health records, significant investments in artificial intelligence technologies, and the strong presence of leading pharmaceutical, biotechnology, and healthcare technology companies. The United States continues to lead regional growth through continuous innovation in digital health, expanding research collaborations, and increasing utilization of AI-powered analytics in clinical development and patient care. Europe represents another significant market for the AI in real-world evidence market, supported by growing healthcare digitization, increasing adoption of real-world evidence in regulatory decision-making, and expanding investments in artificial intelligence research. Asia Pacific is expected to witness the fastest growth during the forecast period owing to expanding healthcare infrastructure, rising pharmaceutical research activities, growing government support for digital healthcare initiatives, and increasing adoption of AI technologies across countries such as China, Japan, India, and South Korea. Latin America is gradually emerging as a promising market due to improving healthcare information systems and increasing digital transformation across healthcare organizations. Meanwhile, the Middle East & Africa region is experiencing steady development supported by healthcare modernization initiatives, growing investments in medical research, and rising adoption of advanced healthcare analytics solutions. Continued technological innovation and increasing demand for evidence-based healthcare decision-making are expected to support the sustained expansion of the AI in real-world evidence market through 2034.